Center Za Psihichno Zdrave Veliko Tarnovo EOOD

The medical center is at the forefront of research in schizophrenia, focusing on innovative treatments that enhance patient outcomes. The ongoing study of emraclidine aims to evaluate its long-term safety and tolerability, providing new insights into managing this complex condition.

• Long-term safety of emraclidine
• Patient tolerability studies
• Innovative treatment approaches

Through these efforts, the center contributes significantly to the understanding and treatment of schizophrenia, offering hope for improved therapeutic strategies.

Specializing in bipolar I disorder, the center is conducting pivotal research on the efficacy and safety of lumateperone for treating manic episodes. This study is crucial in advancing therapeutic options for patients experiencing acute manic episodes or those with mixed features.

• Efficacy of lumateperone
• Acute treatment strategies
• Young Mania Rating Scale (YMRS) assessments

The research aims to refine treatment protocols, enhancing the quality of life for individuals affected by bipolar mania.

In the realm of major depressive disorder (MDD), the center is exploring the potential of aticaprant as an adjunctive therapy. This research focuses on its long-term safety and effectiveness when combined with existing antidepressants, such as SSRIs or SNRIs.

• Adjunctive therapy with aticaprant
• Combination with SSRIs/SNRIs
• Long-term treatment safety

By investigating these combinations, the center aims to enhance therapeutic outcomes for patients with MDD, paving the way for more effective treatment regimens.